• About Us
    • Our Purpose
    • Our Strategy
    • What we do
    • Our Impact
    • Our team
    • Work For Us
    • Volunteer
    • The DMD Registry
    • Action Duchenne Policies
  • Get Support
    • Support Calendar – What’s On
    • Register for Support
      • Time Out – A Space for Mums
      • Dads Against Duchenne
      • Grandparents Together
      • Open Space
      • Group Counselling Programme
    • Recently diagnosed
    • Connect with Others
    • Support for 8-14 yrs ‘Turning Point’
    • Support for 14-25 yrs ‘Yes I Can’
    • Schools
    • Siblings
    • End of Life and Bereavement
  • AD Annual International Conference
    • Highlights from the Action Duchenne Conference 2025
    • Action Duchenne Annual International Conference 2025
  • News, Webinars and Blogs
    • News
    • Webinar Series 2025
      • Webinar Series 2025
      • Webinar recordings
    • Bite-Sized Duchenne Science Live
      • Facts about Duchenne muscular dystrophy
      • Signs and Symptoms of Duchenne Muscular Dystrophy
      • Diagnosis of Duchenne Muscular Dystrophy
      • Crucial Genetic Terminology
      • Genetics – Blueprint of Duchenne Muscular Dystrophy
      • How is Duchenne Muscular Dystrophy Inherited?
    • Hear From Our Community
  • Support Us
  •  0 items - Free
  • Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to secondary navigation
  • Skip to footer

Before Header

  • My account
  •  0 items - Free

Action Duchenne

Header Right

  • About Us
    • Our Purpose
    • Our Strategy
    • What we do
    • Our Impact
    • Our team
    • Work For Us
    • Volunteer
    • The DMD Registry
    • Action Duchenne Policies
  • Get Support
    • Support Calendar – What’s On
    • Register for Support
      • Time Out – A Space for Mums
      • Dads Against Duchenne
      • Grandparents Together
      • Open Space
      • Group Counselling Programme
    • Recently diagnosed
    • Connect with Others
    • Support for 8-14 yrs ‘Turning Point’
    • Support for 14-25 yrs ‘Yes I Can’
    • Schools
    • Siblings
    • End of Life and Bereavement
  • AD Annual International Conference
    • Highlights from the Action Duchenne Conference 2025
    • Action Duchenne Annual International Conference 2025
  • News, Webinars and Blogs
    • News
    • Webinar Series 2025
      • Webinar Series 2025
      • Webinar recordings
    • Bite-Sized Duchenne Science Live
      • Facts about Duchenne muscular dystrophy
      • Signs and Symptoms of Duchenne Muscular Dystrophy
      • Diagnosis of Duchenne Muscular Dystrophy
      • Crucial Genetic Terminology
      • Genetics – Blueprint of Duchenne Muscular Dystrophy
      • How is Duchenne Muscular Dystrophy Inherited?
    • Hear From Our Community
  • Support Us

News

You are here: Home / News

The importance of seeking medical advice – Neuromuscular Research Nurse

December 18, 2017 by abzali123

The use of social media parent groups is invaluable for parents whose children have DMD. They provide a great source of emotional and practical …

The importance of seeking medical advice – Neuromuscular Research NurseRead More

FDA new approach would reduce number of patients treated with placebo

December 11, 2017 by abzali123

The U.S. Food and Drug Administration (FDA) has published its recommendation for a new approach to drug development for rare pediatric diseases. The …

FDA new approach would reduce number of patients treated with placeboRead More

Mark Silverman is poised to deliver his powerful Translarna testimonial to the FDA

September 28, 2017 by abzali123

"I was last in Washington DC two years ago and let's just say there have been a few changes since my last visit. The searing late September heat …

Mark Silverman is poised to deliver his powerful Translarna testimonial to the FDARead More

Acceleron takes back drug rights from Celgene to start pulmonary push

September 21, 2017 by abzali123

Acceleron's long-running collaboration with Celgene on sotatercept has taken another turn, with an amendment of their agreement to give Acceleron the …

Acceleron takes back drug rights from Celgene to start pulmonary pushRead More

Synpromics announces Gene Therapy research partnership with Solid Biosciences

September 21, 2017 by abzali123

Sypromics have announced a new research partnership with Solid Biosciences. Under the terms of the agreement, Synpromics will provide Solid …

Synpromics announces Gene Therapy research partnership with Solid BiosciencesRead More

Neil test news story

September 19, 2017 by abzali123

Newly diagnosed families Newly diagnosed families …

Neil test news storyRead More

PerkinElmer team up with IDG in diagnostic program

September 19, 2017 by abzali123

PerkinElmer have announced a collaboration with In-Depth Genomics (IDG) to support IDG's Whole Genome Sequencing (WGS) Diagnostic Program that will …

PerkinElmer team up with IDG in diagnostic programRead More

Update on CHMP negative opinion for Raxone (idebenone)

September 19, 2017 by abzali123

This afternoon, Action Duchenne has since had confirmation by the Santhera team and this article that this decision has no consequences on their …

Update on CHMP negative opinion for Raxone (idebenone)Read More

First person reaches 15 month mark through Phrixus’ Carmseal-MD

September 18, 2017 by abzali123

Phrixus Pharmaceuticals has announced that the first person living with Duchenne has completed 15 months of treatment with Carmeseal-MD. The …

First person reaches 15 month mark through Phrixus’ Carmseal-MDRead More

Long-term microdystrophin pre-clinical work, moving towards a potential therapy restores muscle function in canines

September 12, 2017 by abzali123

Promising microdystrophin pre-clinical work, moving towards a potential therapy has shown to restore muscle function in the canine model (dogs). …

Long-term microdystrophin pre-clinical work, moving towards a potential therapy restores muscle function in caninesRead More

Parallel 2017 was amazing!

September 12, 2017 by abzali123

Parallel London 2017 was an absolutely inspirational day! 60 incredible people took part for Action Duchenne, representing the entire community, …

Parallel 2017 was amazing!Read More

Sarconeos announced as new potential treatment for Duchenne

September 12, 2017 by abzali123

Biophytis clinical stage drug-candidate Sarconeos demonstrates efficacy in preclinical models of Duchenne muscular dystrophy An abstract …

Sarconeos announced as new potential treatment for DuchenneRead More

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 43
  • Page 44
  • Page 45
  • Page 46
  • Page 47
  • Page 48
  • Go to Next Page »

Footer

Action Duchenne
5th Floor, Mariner House
62 Prince Street
Bristol
BS1 4QD

07535 498 506
info@actionduchenne.org 

 

 

 

 

 

 

 

 

Subscribe to our mailing list

Do you consent to receiving regular email updates? *
Email Format
  • Accessibility
  • Privacy Policy
  • Terms & Conditions

© Action Duchenne - Registered Charity No 1101971 - Scottish Charity No SC043852

Like most websites we use cookies to deliver a personalised service. To use the website as intended please accept cookies.
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT